Please login to the form below
NCI
This page shows the latest NCI news and features for those working in and with pharma, biotech and healthcare.
AZ’s comeback drug cediranib stumbles in phase 3 trial
A phase 2 NCI trial reported in 2014 showed that cediranib plus Lynparza was able to nearly double progression-free survival (PFS) compared to Lynparza alone in patients who had either ... The NCI is carrying out the phase 2/3 GY005 trial of Lynparza
Latest news
-
Merck chases Roche with triple-negative breast cancer data for Keytruda
KEYNOTE-242 is a National Cancer Institute (NCI) sponsored trial testing adjuvant use of the checkpoint inhibitor after neoadjuvant chemotherapy due to generate results in 2026.
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
His successor, Ned Sharpless has been drafted in from his former role as head of the National Cancer Institute (NCI), but remains for now an interim Commissioner, and one certainly less
-
Iovance up on good ASCO abstract data for cervical cancer therapy
Iovance’s approach to immunotherapy was pioneered by Steven Rosenberg of the US National Cancer Institute (NCI).
-
Bluebird’s myeloma CAR-T safety ‘could support outpatient use’
responses with a manageable safety profile we’ve seen for bb2121 to date,” said the trial’s principal investigator James Kochenderfer of the US National Cancer Institute (NCI).
-
Gottlieb signs off with flair – and pledge of further drug price commentary
He now hands over to interim FDA commissioner Ned Sharpless, formerly head of the National Cancer Institute (NCI), but ended his final days in the post with a redoubled focus on
More from news
Approximately 1 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... Collaborating with our
-
Staying ahead in the era of precision medicine
For example, Lung-MAP, a large-scale umbrella trial in non-small cell lung cancer, was one of the first to involve partnerships between several groups including the FDA, NCI, advocacy
-
Country report: The healthcare market in France
National Cancer Institute (NCI) or the National Institute for Prevention and Education for Health (NIPEH).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
AZ and Medimmune bolsters immuno-oncology leadership
roles at the National Cancer Institute (NCI).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
ASCO 2015: What you missed in Chicago
The second area that really impressed me was the large National Cancer Institute (NCI) trial[3] that will look to treat patients with solid tumours based on their genetic mutations and ... Larkin et al 2015 NEJM[3] NCI Prepares to Launch MATCH Trial.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
-
B2B media account director
-
Competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Omicron rise prompts tougher measures in England
- Pfizer/BioNTech promote booster against Omicron
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
